---
title: "Acadia Pharmaceuticals principal accounting officer James Kihara sells 11,421 shares for $297,940.30"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291194117.md"
description: "Acadia Pharmaceuticals principal accounting officer James Kihara sold 11,421 common shares on June 26, 2026, for a total of $297,940.30. The weighted-average sale price was $26.08 per share. Following the transaction, Kihara retained 13,088 shares. This information was published via EDGAR by ACADIA Pharmaceuticals Inc."
datetime: "2026-06-29T22:00:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291194117.md)
  - [en](https://longbridge.com/en/news/291194117.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291194117.md)
---

# Acadia Pharmaceuticals principal accounting officer James Kihara sells 11,421 shares for $297,940.30

-   ACADIA Pharmaceuticals principal accounting officer James Kihara sold 11,421 common shares on June 26, 2026. \* Sale price was USD 26.08 per share on a weighted-average basis. \* Kihara held 13,088 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001816160-26-000009), on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)

## Related News & Research

- [Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference | ACAD Stock News](https://longbridge.com/en/news/294422717.md)
- [How FDA Fast Track For Remlifanserin In Alzheimer’s Psychosis At ACADIA (ACAD) Has Changed Its Investment Story](https://longbridge.com/en/news/294004149.md)
- [ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus](https://longbridge.com/en/news/293825186.md)
- [ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Arrowstreet Capital Limited Partnership](https://longbridge.com/en/news/294166812.md)
- [ACADIA issues press release on FDA Fast Track designation for remlifanserin in Alzheimer’s disease psychosis](https://longbridge.com/en/news/293219067.md)